Grand Pharmaceutical Group Limited (HK:0512) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Grand Pharmaceutical Group Limited has achieved a significant milestone with the successful completion of a Phase III clinical trial for its innovative ophthalmic drug, GPN00833, in China. The drug, designed to treat inflammation and pain after cataract surgery, demonstrated superior efficacy and safety compared to a placebo. This advancement bolsters the company’s position in the ENT drug market and underscores its commitment to innovative R&D and global market expansion.
For further insights into HK:0512 stock, check out TipRanks’ Stock Analysis page.